AML patients with older age were more likely to carry gene mutation such as TET2 and DNMT3A, and these mutations were considered to involve in accumulation of cellular damage and promote progression of MDS to AML [16]. This evidence concerns the gene DNMT3A and myelodysplastic syndrome.